Congress Presentations
Stay informed about the latest scientific and medical research from Axsome.
Neuroscience Education Institute (NEI) 2024 Congress
Colorado Springs, Colorado | November 07 - 10, 2024
Solriamfetol | Excessive Daytime Sleepiness
Effects of Solriamfetol on Cognition in Obstructive Sleep Apnea With Excessive Daytime Sleepiness and Impaired Cognition in the SHARP Clinical Trial
Solriamfetol | Excessive Daytime Sleepiness
Effects of Solriamfetol on Cognition in Patients With Excessive Daytime Sleepiness Associated with Narcolepsy in the Real-World SURWEY Study
Solriamfetol | Excessive Daytime Sleepiness
Real-world Use of Solriamfetol for Excessive Daytime Sleepiness in Patients Reporting Anxiety or Depression in the Real-World SURWEY Study
AXS-05 | Major Depressive Disorder
AXS-05 (Auvelity®) in Major Depressive Disorder: Pooled Data from Two Six-Week Controlled Trials (GEMINI and ASCEND)
AXS-05 | Major Depressive Disorder
Dr. Craig Chepke, MD, DFAPA describes the “AXS-05 (Auvelity®) in Major Depressive Disorder: Pooled Data from Two Six-Week Controlled Trials (GEMINI and ASCEND)” poster
AXS-05 | Major Depressive Disorder
Effects of AXS-05 (Auvelity®) in Improving Anhedonia and Interest-Activity Symptoms of MDD and the Associated Improvements in Functional Impairment
AXS-05 | Major Depressive Disorder
Real-World Treatment Experiences and Expectations by Symptom Severity in Patients With Major Depressive Disorder
AXS-05 | Major Depressive Disorder
Real-World AXS-05 (Auvelity®) Patient Characteristics in Major Depressive Disorder
AXS-05 | Major Depressive Disorder
Clinical Profile of AXS-05 in Treating Alzheimer’s Disease Agitation: Results From The Phase 2/3 Development Program
